Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito

Contributi Scientifici

N. 54 (2020)

Approccio integrato per la gestione di pazienti con disturbi psichiatrici-tabagisti tra U.O. CSM Catanzaro e Centro Antifumo - S.S. Ser.D. Soverato

11 December 2020


The use of tobacco is one of the major social and health problems of our times, the leading cause of preventable death.
The steady reduction in the prevalence of smoking in the general population in recent decades has not been observed in populations with psychiatric disorders.
Hence a pilot project that aims to promote a territorial network between the Mental Health Services and the Anti-Smoking Centers for a global intervention strategy to combat smoking in patients with psychiatric disorders trying to create conditions of “Tobacco Services-Free”, including employees, at any point inside and outside the structure.
The experience made with a Protocol is particularly significant in the first place to dispel the clichés on the problem of smoking and mental illness in accordance with the scientific data present in the literature.
The treatment of these patients can be successful if psychiatric services in addressing the problem offer behavioral motivational support to their patients.
Collaboration with specialist Centers is essential for the treatment of addiction.
Varenicline was effective in helping patients achieve abstinence or reduce the number of cigarettes smoked, and did not show a significant increase in neuropsychiatric adverse events.
It is desirable that all Mental Health Services be able to carry out informational-motivational counseling on
smoking-related risks, favoring access for motivated patients to specific cessation programs in collaboration with specialized services (Anti-Smoking Centers).

Riferimenti bibliografici

  1. Anthenelli R.M., Morris C., Ramey T.S. et al. (2013). Effects of varenicline on smoking cessation in adult with stably treated current or past major depression: a randomized trial. Ann Intern Med, 159: 390-400.
  2. Cahill K., Stevens R., Lancaster T. (2013). Farmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 5: CD009329.
  3. Evins A.E., Cather C., Pratt S.A. et al. (2014). Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA, 311: 145-54.
  4. Gibbons R.D., Mann J.J. (2013). Varenicline, smoking cessation, and neuropsychiatric adverse events. Amk J Psychiatry, 170: 1460-67.
  5. Lugoboni F., Chiamulera C. (2013). Figli di un Dia assente. La dannazione del fumo tra i malati di mente. Tabaccologia, 4: 7-9.
  6. Molero Y., Lichtenstein P., Zetterqvist J., Gumpert C.H., Fazel S. (2015). Varenicline and risk of psychiatric conditions, suicidal behaviors, criminal offending, and transport accidents and offences: population based cohort study. BMJ, 350: h2388.
  7. Pasternak B., Svanstrom H., Hviid A. (2013). Use of varenicline versus bupropion and risk of psychiatric adverse event. Addiction, 108: 1336-43.
  8. Thomas K.H., Martin R.M., Knipe D.W., Higgins J.P., Gunnell D. (2015). Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ, 350: h1109.
  9. Thomas K.H., Martin R.M., Davies N.M., Metcalfe C., Windmeijer F., Gunnell D. (2013). Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Pratice Research Datalink: prospective cohort study. BMJ, 347: f5704.
  10. Vegliach A., Jugovac D., Quartarone Generoso G., Ciarfeo Purich R. (2015). Tabagismo e riduzione del danno. Tabaccologia, 1: 18-19.
  11. Yousefi M.K., Folsom T.D., Fatemi S.H. (2011). A review of varenicline’s efficacy and tolerability in smoking cessation studies in subjects with schizophrenia. J Addict Res Ther, S 4.


Caricamento metriche ...